We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+8.38%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$3.74B
AUM Growth
-$335M
Cap. Flow
-$614M
Cap. Flow %
-16.42%
Top 10 Hldgs %
21.69%
Holding
674
New
53
Increased
215
Reduced
238
Closed
121

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$107M
2
AAPL icon
Apple
AAPL
+$71.8M
3
TRV icon
Travelers Companies
TRV
+$27.6M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$27.4M
5
AXP icon
American Express
AXP
+$26.9M

Sector Composition

Rank Sector Weight
1 Healthcare 28.7%
2 Financials 10.88%
3 Technology 9.76%
4 Communication Services 9.34%
5 Consumer Staples 9.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
LUMN icon
251
Lumen
LUMN
$6.53B
$2.71M 0.07%
107,632
+2,325
+2% +$62.4K
COST icon
252
Costco
COST
$415B
$2.7M 0.07%
16,716
+993
+6% +$157K
IPXL
253
DELISTED
Impax Laboratories, Inc.
IPXL
$2.57M 0.07%
+60,000
New +$2.4M
KPTI icon
254
Karyopharm Therapeutics
KPTI
$168M
$2.53M 0.07%
12,740
+2,000
+19% +$433K
BSX icon
255
Boston Scientific
BSX
$65.8B
$2.48M 0.07%
134,685
-2,810
-2% -$50.4K
MET icon
256
MetLife
MET
$61B
$2.48M 0.07%
57,660
-185,618
-76% -$8.16M
CNI icon
257
Canadian National Railway
CNI
$78.3B
$2.45M 0.07%
44,013
-6,614
-13% -$387K
WBA
258
DELISTED
Walgreens Boots Alliance
WBA
$2.41M 0.06%
28,307
+1,602
+6% +$136K
VTAE
259
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$2.41M 0.06%
+133,000
New +$1.83M
TMUS icon
260
T-Mobile US
TMUS
$193B
$2.38M 0.06%
60,949
+6,311
+12% +$244K
UPS icon
261
United Parcel Service
UPS
$97.6B
$2.38M 0.06%
24,695
-170,070
-87% -$17.4M
MDCO
262
DELISTED
Medicines Co
MDCO
$2.36M 0.06%
63,300
HBI
263
DELISTED
Hanesbrands
HBI
$2.34M 0.06%
+79,627
New +$2.39M
WAT icon
264
Waters Corp
WAT
$36.8B
$2.33M 0.06%
17,349
-58,264
-77% -$7.49M
BXLT
265
DELISTED
BAXALTA INC COM STK (DE)
BXLT
$2.33M 0.06%
59,718
-6,896
-10% -$240K
LDRH
266
DELISTED
LDR HOLDINGS CORP COM STK
LDRH
$2.32M 0.06%
92,500
+48,500
+110% +$1.26M
MUR icon
267
Murphy Oil
MUR
$5.58B
$2.31M 0.06%
103,073
-141,310
-58% -$3.81M
PSA icon
268
Public Storage
PSA
$60.2B
$2.26M 0.06%
9,132
-1,175
-11% -$275K
UN
269
DELISTED
Unilever NV New York Registry Shares
UN
$2.25M 0.06%
52,000
+2,300
+5% +$101K
ZTS icon
270
Zoetis
ZTS
$31.6B
$2.22M 0.06%
46,259
-7,266
-14% -$328K
LXRX icon
271
Lexicon Pharmaceuticals
LXRX
$1.02B
$2.2M 0.06%
+165,000
New +$2.03M
MRSH
272
Marsh
MRSH
$86.3B
$2.15M 0.06%
38,715
+8,976
+30% +$495K
TTPH
273
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$2.14M 0.06%
10,680
+5,250
+97% +$1.05M
CCP
274
DELISTED
Care Capital Properties, Inc.
CCP
$2.14M 0.06%
+70,000
New +$2.23M
VIPS icon
275
Vipshop
VIPS
$6.84B
$2.12M 0.06%
139,000
-232,000
-63% -$4.07M

Similar funds

Candriam SCA's Q4 2015 Portfolio in Review

As of Q4 2015, Candriam SCA held 674 positions worth $3.74B, down 8.2% from $4.07B the previous quarter. Its ten largest holdings account for 22% of the portfolio.

Candriam SCA withdrew a net $614M in Q4 2015, closing 121 positions and reducing 238 holdings. Its most notable exit was Amgen, an estimated $107M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 29% of assets, down from 29% a quarter earlier, followed by Financials and Technology.

Against the trend, Candriam SCA opened a new position in Alphabet (Google) Class A worth $118M.

  • Candriam SCA's largest Q4 2015 buy was Alphabet (Google) Class A: 3,043,280 shares worth $118M.
  • Candriam SCA added most to Intel in Q4 2015, an estimated $61.2M increase.
  • Candriam SCA's biggest Q4 2015 reduction was Colgate-Palmolive, cutting an estimated $21.3M.
  • Candriam SCA fully exited Amgen in Q4 2015, selling an estimated $107M.
  • Candriam SCA's ten largest holdings make up 22% of its $3.74B portfolio in Q4 2015.
  • Candriam SCA opened 53 new positions and closed 121 in Q4 2015.
  • Candriam SCA's portfolio value fell 8.2% quarter-over-quarter to $3.74B.

Based on Candriam SCA's 13F filing for Q4 2015, filed 25 Jan 2016.